Arcus Biosciences (RCUS) Q2 FY26 earnings call

Arcus Biosciences is rapidly advancing its oncology and immunology pipeline, with a primary focus on casdatifan, its next-generation HIF-2-alpha inhibitor, which is positioned to become a foundational therapy across all lines of clear cell RCC treatment. The company is leveraging strategic collaborations to expand its development program efficiently, while also progressing a broad immunology portfolio and preparing for key data readouts for casdatifan and quemliclustat. Strong financial positioning supports these initiatives, aiming for significant value creation.